152 related articles for article (PubMed ID: 32529756)
1. Association between low body weight and cytochrome P-450 enzyme activity in patients with anorexia nervosa.
Sandvik P; Lydersen S; Hegstad S; Spigset O
Pharmacol Res Perspect; 2020 Jun; 8(3):e00615. PubMed ID: 32529756
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
3. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
Damkier P; Brøsen K
Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
[TBL] [Abstract][Full Text] [Related]
4. Effects of Khat (Catha edulis) use on catalytic activities of major drug-metabolizing cytochrome P450 enzymes and implication of pharmacogenetic variations.
Bedada W; de Andrés F; Engidawork E; Hussein J; LLerena A; Aklillu E
Sci Rep; 2018 Aug; 8(1):12726. PubMed ID: 30143732
[TBL] [Abstract][Full Text] [Related]
5. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
9. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.
Li H; Canet MJ; Clarke JD; Billheimer D; Xanthakos SA; Lavine JE; Erickson RP; Cherrington NJ
Drug Metab Dispos; 2017 Dec; 45(12):1317-1325. PubMed ID: 28986475
[TBL] [Abstract][Full Text] [Related]
11. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
[TBL] [Abstract][Full Text] [Related]
12. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.
Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA
Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694
[TBL] [Abstract][Full Text] [Related]
13. Elevated 4β-hydroxycholesterol/cholesterol ratio in anorexia nervosa patients.
Hole K; Heiberg PL; Gjestad C; Mehus LL; Rø Ø; Molden E
Pharmacol Res Perspect; 2018 Oct; 6(5):e00430. PubMed ID: 30214813
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the impact of cantharidin on rat CYP enzymes by using a cocktail of probe drugs.
Zhou CJ; Qiao LM; Zhao LH; Li ZY
Fitoterapia; 2015 Dec; 107():49-53. PubMed ID: 26498206
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine.
Fang J; Coutts RT; McKenna KF; Baker GB
Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):592-9. PubMed ID: 9840430
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cytochrome P450 enzymes by thymoquinone in human liver microsomes.
Albassam AA; Ahad A; Alsultan A; Al-Jenoobi FI
Saudi Pharm J; 2018 Jul; 26(5):673-677. PubMed ID: 29989011
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
20. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression.
Temesvári M; Kóbori L; Paulik J; Sárváry E; Belic A; Monostory K
J Pharmacol Exp Ther; 2012 Apr; 341(1):294-305. PubMed ID: 22262920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
